JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB77239

FITC Anti-IgE antibody [4H10]

5

(1 Review)

|

(1 Publication)

Mouse Monoclonal IgE antibody - conjugated to FITC. Suitable for Flow Cyt and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Native Full Length Protein corresponding to Human IGHE.

View Alternative Names

Immunoglobulin heavy constant epsilon, Ig epsilon chain C region, Ig epsilon chain C region ND, IGHE

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

4H10

Isotype

IgG1

Conjugation

FITC

Excitation/Emission

Ex: 495nm, Em: 519nm

Carrier free

No

Reacts with

Human

Applications

Flow Cyt

applications

Immunogen

Native Full Length Protein corresponding to Human IGHE.

P01854

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "guaranteed", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p><a href='/en-us/products/primary-antibodies/fitc-mouse-igg1-b11-6-isotype-control-ab91356'>ab91356</a> - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.</p>" } } }

Product details

The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC.

Properties and storage information

Form
Liquid
Purification technique
Size-exclusion chromatography
Storage buffer
pH: 7.4 Preservative: 0.097% Sodium azide Constituents: 0.2% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The IgE protein [also known as immunoglobulin E] is a type of antibody with a molecular mass of approximately 190 kDa. IgE is expressed primarily on the surface of mast cells and basophils. It plays a central role in the immune system by binding to allergens and triggering the release of inflammatory mediators from mast cells and basophils. IgE's high-affinity binding to its receptor FcεRI on these effector cells facilitates this process. IgE's activity is central to initiating immediate hypersensitivity reactions which are a part of the body's immune response.
Biological function summary

The IgE protein functions as a mediator in allergic reactions. It does not operate as part of a complex but directly interacts with allergens and the IgE-specific receptors on immune cells. IgE's role is important in defense against parasitic infections where it performs a protective function by promoting eosinophil activation and degranulation. This action helps the body to expel the parasites. In the absence of parasitic infection IgE's function translates into its role in allergic responses where it becomes responsible for the symptoms associated with allergic diseases.

Pathways

IgE is an important player in the immune response pathway. The protein interacts with allergy-related pathways such as the T helper 2 (Th2) pathway. IgE's role in this pathway involves cooperation with cytokines notably IL-4 and IL-13 which are produced by Th2 cells and promote IgE synthesis in B cells. Also IgE is linked to the FcεRI receptor signaling pathway that initiates the release of histamines and other mediators when IgE binds to an allergen leading to an allergic response.

IgE is closely linked to allergic conditions like asthma and allergic rhinitis. These conditions result from IgE-mediated inflammatory responses that affect the respiratory system. In asthma IgE antibodies play a role in airway inflammation and hyperreactivity by promoting the activation of multiple immune cells including eosinophils and mast cells. IgE's involvement in allergic rhinitis manifests through similar mechanisms with nasal inflammation and irritation. IgE's interaction with other proteins such as histamine-releasing factor exacerbates these conditions by increasing the release of histamine which intensifies the allergic symptoms.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed : 20176268, PubMed : 22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed : 17576170, PubMed : 20176268).. Isoform 1. Constant region of secreted IgE, also known as the Fc region of IgE antibody. Mediates IgE effector functions on myeloid and lymphoid cells primarily via two Fc receptors, the high-affinity IgE Fc receptor complex/FCER1A : MS4A2 : FCGR1A and the low-affinity FCER2 receptor, which upon antigen/allergen cross-linking initiate signaling pathways that lead to immune cell activation and differentiation (PubMed : 2167225, PubMed : 25629393, PubMed : 33840121, PubMed : 7544003, PubMed : 8114916, PubMed : 8551243). Triggers the immediate hypersensitivity response to allergens as a host defense mechanism against helminth parasites, pathogenic bacteria and venom toxicity. When dysregulated, it can elicit harmful life-threatening allergic and anaphylactic reactions (PubMed : 25629393, PubMed : 33840121, PubMed : 7544003, PubMed : 8114916, PubMed : 8551243). Stimulates the high-affinity IgE Fc receptor complex/FCER1A : MS4A2 : FCGR1A on mast cells, basophils and eosinophils leading to secretion of vasoactive amines, lipid mediators and cytokines that contribute to inflammatory response, tissue remodeling and cytotoxicity against microbes (PubMed : 25629393, PubMed : 8114916, PubMed : 8551243). On macrophages, cross-linking of FCER2 by IgE immune complexes induces intracellular killing of parasites through activation of L-Arginine-nitric oxide pathway (PubMed : 7544003). Activates macrophages to kill tumor cells via antigen-specific antibody-dependent cytotoxicity (ADCC). Triggers differentiation of quiescent M0 macrophages toward M1 state and reprograms M2 macrophages toward a proinflammatory state with antitumor functions (PubMed : 30956175). Stimulates FCER2 on B cells and initiates IgE-dependent antigen uptake and presentation to T cells (PubMed : 2167225).. Isoform 2. Constant region of membrane-bound IgE (long mIgE), part of the B cell receptor complex (BCR). Upon antigen cross-linking triggers quick BCR signaling, ensuring survival of IgE-switched B cells and differentiation into plasma cells, thus regulating both primary and memory IgE responses.. Isoform 3. Constant region of membrane-bound IgE (short mIgE), part of the B cell receptor complex (BCR). Upon antigen cross-linking initiates slower but sustained BCR signaling that negatively regulates mature B cell proliferation.
See full target information IGHE

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Molecular pharmacology 79:69-76 PubMed20943773

2010

Pharmacological characterization of MK-7246, a potent and selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells) antagonist.

Applications

Flow Cyt

Species

Human

Francois G Gervais,Nicole Sawyer,Rino Stocco,Martine Hamel,Connie Krawczyk,Susan Sillaots,Danielle Denis,Elizabeth Wong,Zhaoyin Wang,Michel Gallant,William M Abraham,Deborah Slipetz,Michael A Crackower,Gary P O'Neill
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com